Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 10/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395456 | 0.85 | KDM4E (0.43) | — | |
| SCHEMBL27698191 | 0.81 | IKBKB (0.41) | — | |
| SCHEMBL3395593 | 0.81 | IKBKB (0.32) | — | |
| SCHEMBL3389162 | 0.80 | PLAT (0.34) | — | |
| SCHEMBL3391379 | 0.72 | HPGDS (0.45) | — | |
| SCHEMBL31404482 | 0.71 | HCAR2 (0.39) | KDM5A | |
| SCHEMBL3988315 | 0.70 | TLR9 (0.40) | KDM5A | |
| SCHEMBL3395473 | 0.67 | KDM4E (0.44) | — | |
| SCHEMBL18130738 | 0.66 | JAK2 (0.43) | — | |
| SCHEMBL28064009 | 0.65 | SCD5 (0.37) | SCD5FASNMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1758578-B1 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1758578-A4 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1758578-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | Smithkline Beecham Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006002434-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | IKBKG, IRAK2, NFKBIA | SCD5 1972/4885FASN 1516/4885KDM5A 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.